NZ health service takes on GTG over licence fees
24 August, 2004 by Graeme O'NeillOn the eve of its landmark patent-infringement case against US gene-testing company Applera Corp, Melbourne-based Genetic Technologies (ASX:GTG) has been hit with a New Zealand challenge to its right to charge licence fees for access to its non-coding DNA patents.
Victoria Fellowship winner works on relaxin
20 August, 2004 by Melissa TrudingerVictoria Fellowship winner Daniel Scott will be using his prize money to spend some time at Stanford University in the US working on an inhibitor of pregnancy hormone relaxin.
Malaria: the wizard of oz
19 August, 2004 by Graeme O'NeillThe ancient Chinese pharmacopoeia has bequeathed Western medicine a dragon-slaying drug that promises to save the lives of up to two million people a year – half of them children under the age of two – in regions of the world haunted by drug-resistant strains of malaria.
Meditech boosted by Phase II results
19 August, 2004 by Renate KrelleWith all patients in the first stage of its Phase II HyCamp clinical trial escaping the gastrointestinal side-effects normally associated with standard colon cancer treatment irinotecan, Meditech (ASX:MTR) has announced it will forge ahead with second stage of its trial.
A Conneticut Yankee in Prana's court
17 August, 2004 by Graeme O'NeillPrana Biotechnology’s (ASX:PBT, NASDAQ:PRAN ) new American CEO Jonas Alsenas began taking an interest in the company several years ago, when he felt the faint tremors of a paradigm shift in the Alzheimer’s disease research field.
Somnomed propels itself towards the market
09 August, 2004 by Melissa TrudingerSydney-based company Somnomed is preparing to list on the ASX later this month, with an IPO expected to raise AUD$12 million through the sale of 40 million shares at $0.30 per share.
New test developed for oesophageal cancer
04 August, 2004 by Staff WritersResearchers at the Wolfson Institute for Biomedical Research at University College London have developed a test to detect cancer of the oesophagus which could improve survival rates.
CBio gears up for Phase II trials of autoimmune drug
27 July, 2004 by Melissa TrudingerQueensland biotech CBio presented its Phase I clinical trial results at the World Congress of Immunology in Montreal last week, and is raising capital and readying itself for Phase II trials.
QIMR, Tissue Therapies make cell supply deal
22 July, 2004 by Renate KrelleResearchers at the Queensland Institute of Medical Research (QIMR) have struck a formal deal with recently-listed Tissue Therapies (ASX:TIS) to boost the yield and quality of dendritic cells for their cancer vaccine using the company's cellular growth enhancer VitroGro.
New trials planned for Melbourne team's cancer vaccine
21 July, 2004 by Graeme O'NeillIt began as a routine trial of a therapeutic vaccine for melanoma, but it had a spectacular and unexpected outcome -- all but two of the 19 patients treated with the vaccine are still alive two years after beginning treatment.
Cancer researcher humbled by major award
21 July, 2004 by Susan WilliamsonDr Susan Clark from the Sydney Cancer Centre and the Garvan Institute has been awarded a major international prize for her contribution to DNA methylation research over the last 10 years.
Medica morphs into Cytopia, wins record ARC grant
21 July, 2004 by Melissa Trudinger and Renate KrelleMedica Holdings officially became Cytopia (ASX:CYT) this week, as it took the next big step from being a biotech investment company to a biotech company in its own right.
Psiron license triggers $2.5m raising
13 July, 2004 by Renate KrelleSydney-based biotech Psiron (ASX:PXS) is putting its house in order -- having announced its intention to license oncolytic enteroviruses technology from University of Newcastle alumnus Virotarg, the company today said the license would trigger an AUD$2.5 million capital raising.
Acrux signs CSL deal, waits to list
07 July, 2004 by Melissa TrudingerAcrux has signed an agreement with CSL for the distribution of Acrux's testosterone MDTS (metered dose transdermal spray) treatment in Australia and New Zealand.
AustCancer subsidiary signs distribution deal
06 July, 2004 by Renate KrelleACT US, the US subsidiary of oncology specialist Australian Cancer Technology ("AustCancer") (ASX: ACU) has signed a distribution deal for its revisys range of nutritional supplements.
